Cargando…

A huge recurrent retroperitoneal inflammatory myofibroblastic tumor implicating renal and ureter: a case report

Inflammatory myofibroblastic tumor (IMT) is a rare sarcoma with unique molecular characteristics. It also has typical fasciitis-like, dense spindle cells and hypocellular fibrous histologic patterns and can occur at any age. The etiology of IMT is unknown and a complete treatment and monitoring plan f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Tianle, Gao, Pan, Gao, Jingjing, Liu, Xi, Zhang, Xiansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798890/
https://www.ncbi.nlm.nih.gov/pubmed/35116312
http://dx.doi.org/10.21037/tcr-21-899
_version_ 1784641927981826048
author Zhu, Tianle
Gao, Pan
Gao, Jingjing
Liu, Xi
Zhang, Xiansheng
author_facet Zhu, Tianle
Gao, Pan
Gao, Jingjing
Liu, Xi
Zhang, Xiansheng
author_sort Zhu, Tianle
collection PubMed
description Inflammatory myofibroblastic tumor (IMT) is a rare sarcoma with unique molecular characteristics. It also has typical fasciitis-like, dense spindle cells and hypocellular fibrous histologic patterns and can occur at any age. The etiology of IMT is unknown and a complete treatment and monitoring plan for IMT have not been developed. We have found a rare case about a huge recurrent IMT implicating renal and ureter. The patient was accompanied by a history of a lesion sized 15.5 cm × 11.5 cm × 10.5 cm as a retroperitoneal IMT, and the first tumor resection was performed 12 months ago. The patient, who suffered from tumor recurrence within 1 year and whose recurrent tumor also invaded into the renal parenchymal was given a retroperitoneal neoplasm resection plus right nephrectomy. In order to clarify the pathological features, the histological specimens of recurrent retroperitoneal IMT were examined as well as primary retroperitoneal IMT, and immunohistochemical (IHC) stains showed that the spindle cells were positive for vimentin and negative for anaplastic lymphoma kinase (ALK). At 24 months follow-up, the patient recovered well and there was no evidence of tumor recurrence. This case report is conducive to understanding this rare tumor. When conditions permit, complete surgical resection is the recommended treatment for primary and recurrent IMT.
format Online
Article
Text
id pubmed-8798890
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87988902022-02-02 A huge recurrent retroperitoneal inflammatory myofibroblastic tumor implicating renal and ureter: a case report Zhu, Tianle Gao, Pan Gao, Jingjing Liu, Xi Zhang, Xiansheng Transl Cancer Res Case Report Inflammatory myofibroblastic tumor (IMT) is a rare sarcoma with unique molecular characteristics. It also has typical fasciitis-like, dense spindle cells and hypocellular fibrous histologic patterns and can occur at any age. The etiology of IMT is unknown and a complete treatment and monitoring plan for IMT have not been developed. We have found a rare case about a huge recurrent IMT implicating renal and ureter. The patient was accompanied by a history of a lesion sized 15.5 cm × 11.5 cm × 10.5 cm as a retroperitoneal IMT, and the first tumor resection was performed 12 months ago. The patient, who suffered from tumor recurrence within 1 year and whose recurrent tumor also invaded into the renal parenchymal was given a retroperitoneal neoplasm resection plus right nephrectomy. In order to clarify the pathological features, the histological specimens of recurrent retroperitoneal IMT were examined as well as primary retroperitoneal IMT, and immunohistochemical (IHC) stains showed that the spindle cells were positive for vimentin and negative for anaplastic lymphoma kinase (ALK). At 24 months follow-up, the patient recovered well and there was no evidence of tumor recurrence. This case report is conducive to understanding this rare tumor. When conditions permit, complete surgical resection is the recommended treatment for primary and recurrent IMT. AME Publishing Company 2021-10 /pmc/articles/PMC8798890/ /pubmed/35116312 http://dx.doi.org/10.21037/tcr-21-899 Text en 2021 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Case Report
Zhu, Tianle
Gao, Pan
Gao, Jingjing
Liu, Xi
Zhang, Xiansheng
A huge recurrent retroperitoneal inflammatory myofibroblastic tumor implicating renal and ureter: a case report
title A huge recurrent retroperitoneal inflammatory myofibroblastic tumor implicating renal and ureter: a case report
title_full A huge recurrent retroperitoneal inflammatory myofibroblastic tumor implicating renal and ureter: a case report
title_fullStr A huge recurrent retroperitoneal inflammatory myofibroblastic tumor implicating renal and ureter: a case report
title_full_unstemmed A huge recurrent retroperitoneal inflammatory myofibroblastic tumor implicating renal and ureter: a case report
title_short A huge recurrent retroperitoneal inflammatory myofibroblastic tumor implicating renal and ureter: a case report
title_sort huge recurrent retroperitoneal inflammatory myofibroblastic tumor implicating renal and ureter: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798890/
https://www.ncbi.nlm.nih.gov/pubmed/35116312
http://dx.doi.org/10.21037/tcr-21-899
work_keys_str_mv AT zhutianle ahugerecurrentretroperitonealinflammatorymyofibroblastictumorimplicatingrenalandureteracasereport
AT gaopan ahugerecurrentretroperitonealinflammatorymyofibroblastictumorimplicatingrenalandureteracasereport
AT gaojingjing ahugerecurrentretroperitonealinflammatorymyofibroblastictumorimplicatingrenalandureteracasereport
AT liuxi ahugerecurrentretroperitonealinflammatorymyofibroblastictumorimplicatingrenalandureteracasereport
AT zhangxiansheng ahugerecurrentretroperitonealinflammatorymyofibroblastictumorimplicatingrenalandureteracasereport
AT zhutianle hugerecurrentretroperitonealinflammatorymyofibroblastictumorimplicatingrenalandureteracasereport
AT gaopan hugerecurrentretroperitonealinflammatorymyofibroblastictumorimplicatingrenalandureteracasereport
AT gaojingjing hugerecurrentretroperitonealinflammatorymyofibroblastictumorimplicatingrenalandureteracasereport
AT liuxi hugerecurrentretroperitonealinflammatorymyofibroblastictumorimplicatingrenalandureteracasereport
AT zhangxiansheng hugerecurrentretroperitonealinflammatorymyofibroblastictumorimplicatingrenalandureteracasereport